Compare VENUS REMEDIES with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs AUROBINDO PHARMA - Comparison Results

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES AUROBINDO PHARMA VENUS REMEDIES/
AUROBINDO PHARMA
 
P/E (TTM) x -13.6 17.8 - View Chart
P/BV x 0.9 3.9 23.5% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 VENUS REMEDIES   AUROBINDO PHARMA
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
AUROBINDO PHARMA
Mar-19
VENUS REMEDIES/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs126830 15.2%   
Low Rs61527 11.6%   
Sales per share (Unadj.) Rs301.8333.9 90.4%  
Earnings per share (Unadj.) Rs-24.940.4 -61.6%  
Cash flow per share (Unadj.) Rs2.551.8 4.9%  
Dividends per share (Unadj.) Rs02.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs293.3237.1 123.7%  
Shares outstanding (eoy) m12.34585.91 2.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.0 15.2%   
Avg P/E ratio x-3.816.8 -22.4%  
P/CF ratio (eoy) x36.713.1 280.3%  
Price / Book Value ratio x0.32.9 11.1%  
Dividend payout %06.2 0.0%   
Avg Mkt Cap Rs m1,154397,569 0.3%   
No. of employees `0000.917.9 5.2%   
Total wages/salary Rs m39325,849 1.5%   
Avg. sales/employee Rs Th4,026.110,956.9 36.7%   
Avg. wages/employee Rs Th425.01,447.7 29.4%   
Avg. net profit/employee Rs Th-331.81,324.3 -25.1%   
INCOME DATA
Net Sales Rs m3,724195,636 1.9%  
Other income Rs m231,553 1.4%   
Total revenues Rs m3,747197,189 1.9%   
Gross profit Rs m39539,519 1.0%  
Depreciation Rs m3386,680 5.1%   
Interest Rs m3542,626 13.5%   
Profit before tax Rs m-27531,767 -0.9%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m327,269 0.4%   
Profit after tax Rs m-30723,645 -1.3%  
Gross profit margin %10.620.2 52.5%  
Effective tax rate %-11.522.9 -50.2%   
Net profit margin %-8.212.1 -68.2%  
BALANCE SHEET DATA
Current assets Rs m2,638153,645 1.7%   
Current liabilities Rs m2,305120,429 1.9%   
Net working cap to sales %8.917.0 52.7%  
Current ratio x1.11.3 89.7%  
Inventory Days Days135135 100.2%  
Debtors Days Days4664 72.7%  
Net fixed assets Rs m4,871103,909 4.7%   
Share capital Rs m123586 21.1%   
"Free" reserves Rs m3,496138,322 2.5%   
Net worth Rs m3,619138,908 2.6%   
Long term debt Rs m1,3741,800 76.4%   
Total assets Rs m7,509264,544 2.8%  
Interest coverage x0.213.1 1.7%   
Debt to equity ratio x0.40 2,931.5%  
Sales to assets ratio x0.50.7 67.1%   
Return on assets %0.69.9 6.4%  
Return on equity %-8.517.0 -49.8%  
Return on capital %1.623.8 6.6%  
Exports to sales %049.6 0.0%   
Imports to sales %13.918.8 73.9%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs m51736,741 1.4%   
Fx inflow Rs m097,316 0.0%   
Fx outflow Rs m51740,589 1.3%   
Net fx Rs m-51756,727 -0.9%   
CASH FLOW
From Operations Rs m51416,220 3.2%  
From Investments Rs m-123-28,768 0.4%  
From Financial Activity Rs m-38719,191 -2.0%  
Net Cashflow Rs m46,656 0.1%  

Share Holding

Indian Promoters % 32.9 54.1 60.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 8.0 2.3%  
FIIs % 0.6 27.7 2.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 10.2 651.0%  
Shareholders   20,121 69,601 28.9%  
Pledged promoter(s) holding % 36.4 8.6 424.8%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  JUBILANT PHARMOVA   DIVIS LABORATORIES  

Compare VENUS REMEDIES With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Recover From Day's Low to End Strong; TCS & Wipro Rally Over 3.5%(Closing)

Indian share markets recouped early losses during closing hours and ended today's volatile session higher, helped by gains in metals and banking stocks.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)

Sep 15, 2020 | Updated on Sep 15, 2020

For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

An India Revival Stock I'm Bullish On...(Profit Hunter)

Apr 9, 2021

This could take India to the position of 3rd largest economy.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

Why the Market Fell Yesterday(Fast Profits Daily)

Apr 6, 2021

In this video, I'll tell you the two reasons why the market fell on Monday and how you can prepare yourself for such events in the future.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Apr 15, 2021 03:37 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - STERLING BIOTECH COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS